Search
PROFILE Bootcamp in Entrepreneurial Innovation in Orphan Diseases, October 23-25, 2017, Leuven, Belgium.
Breaking innovations in rare diseases are at the centre of this PROFILE Bootcamp, which brings together junior & senior researchers, clinicians, pharmaceutical industry and policymakers.
Read moreEuropean Hematology Association publishes new journal with Wolters Kluwer
The European Hematology Association, the largest Europe-based association of hematologists, launched its new journal HemaSphere with publisher Wolters Kluwer at the 22nd Annual Congress of EHA in Madrid.
Read moreLymphoid malignancies dissected in Warsaw
The EHA–PTHiT Tutorial on Lymphoid Malignancies was held on March 17-18, 2017 in Warsaw, Poland. 96% of meeting attendees were satisfied with the tutorial saying that their expectations are met.
Read moreLymphomas from A to Z
Nineteen countries from 3 continents were represented during the EHA-SWG Scientific Meeting on Rare Lymphomas on March 10-12, 2017 in Barcelona, Spain.
Read moreEuroBloodNet aims for better care for patients with rare blood disorders
ERNs is an initiative of the European Commission and consist of networks of healthcare providers and centers of excellence in Europe aimed at improving quality, safety, and access to highly specialised healthcare.
Read moreImpact of new technologies on diagnosis and treatment of anemias highlighted in scientific meeting
Hematologists from 18 countries and 4 continents learned more about the new techniques for diagnosis and treatment of anemias during the EHA-SWG Scientific Meeting on Anemias on February 2-4, 2017 in Barcelona, Spain.
Read moreEHA in the BioMed Alliance: joining forces for biomedical research
At a recent meeting at the European Parliament, Prof.
Read morePress Release: Economic burden of blood disorders in EU is €23 billion
The economic burden of blood disorders across the European Union, Iceland, Norway and Switzerland amounts to €23 billion per year.
Read moreSGN-CD33A Combined with Hypomethylating Therapy Produces High Remission Rates among Older Patients with AML
Acute myeloid leukemia (AML) is an aggressive form of blood cancer in which the majority of cases express CD33 on the surface of the leukemia cells.
Read moreKiller antibodies against AML
Most patients with acute myeloid leukemia (AML) can only be cured when a stem cell transplant induces an immune response against the patient’s leukemia.
Read more